Macrocyclics: An Original Dallas Biotech Company

(from left to right) Garry Kiefer, PhD, Macrocyclics CEO, and Dean Sherry, PhD, The University of Texas at Dallas

The brainchild of one of The University of Texas at Dallas’ most distinguished chemistry professors has been a profitable business since its founding in 1995, with global reach that produces specialized chemical compounds for the pharmaceutical industry and researchers worldwide. The Plano, Texas, company – Macrocyclics Inc. – has remained a catalyst for innovation while employing UT Dallas alumni and providing hands-on training to students.

 Public investment in university research benefits not only the shareholders but also society. By fueling economic development and by enabling scientists to continue pushing boundaries, that investment yields discoveries that change the world. UT Dallas’ first startup company – Macrocyclics – illustrates this transformative impact.